JP2015083565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015083565A5 JP2015083565A5 JP2014190339A JP2014190339A JP2015083565A5 JP 2015083565 A5 JP2015083565 A5 JP 2015083565A5 JP 2014190339 A JP2014190339 A JP 2014190339A JP 2014190339 A JP2014190339 A JP 2014190339A JP 2015083565 A5 JP2015083565 A5 JP 2015083565A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treating
- preventing
- disease according
- eye disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 208000030533 eye disease Diseases 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014190339A JP5856264B2 (ja) | 2013-09-20 | 2014-09-18 | ポリエチレングリコール含有組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013195329 | 2013-09-20 | ||
| JP2013195329 | 2013-09-20 | ||
| JP2014190339A JP5856264B2 (ja) | 2013-09-20 | 2014-09-18 | ポリエチレングリコール含有組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240775A Division JP2016094442A (ja) | 2013-09-20 | 2015-12-10 | ポリエチレングリコール含有組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015083565A JP2015083565A (ja) | 2015-04-30 |
| JP2015083565A5 true JP2015083565A5 (enExample) | 2015-08-20 |
| JP5856264B2 JP5856264B2 (ja) | 2016-02-09 |
Family
ID=52688941
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014190339A Expired - Fee Related JP5856264B2 (ja) | 2013-09-20 | 2014-09-18 | ポリエチレングリコール含有組成物 |
| JP2015240775A Pending JP2016094442A (ja) | 2013-09-20 | 2015-12-10 | ポリエチレングリコール含有組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240775A Pending JP2016094442A (ja) | 2013-09-20 | 2015-12-10 | ポリエチレングリコール含有組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160228420A1 (enExample) |
| EP (1) | EP3047850A4 (enExample) |
| JP (2) | JP5856264B2 (enExample) |
| KR (1) | KR20160060656A (enExample) |
| CN (1) | CN105555271A (enExample) |
| AU (1) | AU2014322111A1 (enExample) |
| BR (1) | BR112016006153A2 (enExample) |
| CA (1) | CA2924628A1 (enExample) |
| EA (1) | EA201690621A1 (enExample) |
| HK (2) | HK1221407A1 (enExample) |
| IL (1) | IL244648A0 (enExample) |
| MX (1) | MX2016003566A (enExample) |
| MY (1) | MY163236A (enExample) |
| PH (1) | PH12016500461A1 (enExample) |
| SG (1) | SG11201602020QA (enExample) |
| TW (1) | TW201518291A (enExample) |
| WO (1) | WO2015041294A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9987368B2 (en) | 2015-03-17 | 2018-06-05 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising polypeptide |
| CN107427587A (zh) | 2015-03-18 | 2017-12-01 | 参天制药株式会社 | 缓释性医药组合物 |
| WO2016208742A1 (ja) * | 2015-06-25 | 2016-12-29 | 参天製薬株式会社 | 注射剤 |
| AR105215A1 (es) * | 2015-07-01 | 2017-09-13 | Santen Pharmaceutical Co Ltd | Formulación de depósito que contiene ésteres de ácido cítrico |
| CN106902117A (zh) * | 2015-12-23 | 2017-06-30 | 瑞阳(苏州)生物科技有限公司 | 一种预防或治疗脉络膜新生血管形成的药物 |
| WO2018054077A1 (en) * | 2016-09-26 | 2018-03-29 | Reyoung (Suzhou) Biology Science & Technology Co., Ltd | Composition for treating ocular diseases and methods of usage and making |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA833692B (en) * | 1982-05-28 | 1985-02-27 | Beecham Group Plc | Pharmaceutical formulations |
| JPS59101478A (ja) * | 1982-11-29 | 1984-06-12 | Sunstar Inc | リグスチライドを安定に配合した水系組成物 |
| JPH09110698A (ja) * | 1995-10-19 | 1997-04-28 | Taiho Yakuhin Kogyo Kk | 経口用医薬組成物の製造法 |
| ATE512950T1 (de) * | 2004-02-17 | 2011-07-15 | Santen Pharmaceutical Co Ltd | Neue cyclische verbindung mit 4- pyridylalkylthiogruppe mit darin eingeführtem (un)substituiertem amino |
| JP4626353B2 (ja) * | 2004-02-17 | 2011-02-09 | 参天製薬株式会社 | 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物 |
| ES2368153T3 (es) * | 2004-02-17 | 2011-11-14 | Santen Pharmaceutical Co., Ltd. | Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo. |
| US20060153920A1 (en) * | 2004-09-24 | 2006-07-13 | Ketan Amin | Lyophilized pharmaceutical compositions |
| WO2006086750A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Liquid formulations for treatment of diseases or conditions |
| US20070149593A1 (en) | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| MX2009012879A (es) | 2007-07-20 | 2010-01-14 | Alcon Inc | Formulacion farmaceutica para suministrar a los ojos compuestos que inhiben el receptor tirosina cinasa (rtki). |
| WO2009070687A1 (en) * | 2007-11-26 | 2009-06-04 | Merial Limited | Solvent systems for pour-on formulations for combating parasites |
| CN102340993A (zh) | 2009-03-03 | 2012-02-01 | 爱尔康研究有限公司 | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 |
| MY157122A (en) * | 2009-07-17 | 2016-05-13 | Santen Pharmaceutical Co Ltd | 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl]thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzene-sulfonate, crystal of same, polymorph thereof, and processes for production thereof |
| ES2609106T5 (es) * | 2010-01-28 | 2020-11-10 | Eagle Pharmaceuticals Inc | Formulaciones de bendamustina |
-
2014
- 2014-09-18 JP JP2014190339A patent/JP5856264B2/ja not_active Expired - Fee Related
- 2014-09-18 EP EP14845745.0A patent/EP3047850A4/en active Pending
- 2014-09-18 AU AU2014322111A patent/AU2014322111A1/en not_active Abandoned
- 2014-09-18 TW TW103132199A patent/TW201518291A/zh unknown
- 2014-09-18 MY MYPI2016000477A patent/MY163236A/en unknown
- 2014-09-18 HK HK16109575.6A patent/HK1221407A1/en unknown
- 2014-09-18 US US15/023,207 patent/US20160228420A1/en not_active Abandoned
- 2014-09-18 EA EA201690621A patent/EA201690621A1/ru unknown
- 2014-09-18 KR KR1020167008149A patent/KR20160060656A/ko not_active Withdrawn
- 2014-09-18 CA CA2924628A patent/CA2924628A1/en not_active Abandoned
- 2014-09-18 CN CN201480051151.8A patent/CN105555271A/zh active Pending
- 2014-09-18 WO PCT/JP2014/074698 patent/WO2015041294A1/ja not_active Ceased
- 2014-09-18 MX MX2016003566A patent/MX2016003566A/es unknown
- 2014-09-18 BR BR112016006153A patent/BR112016006153A2/pt not_active IP Right Cessation
- 2014-09-18 SG SG11201602020QA patent/SG11201602020QA/en unknown
- 2014-09-18 HK HK16108793.4A patent/HK1220632A1/zh unknown
-
2015
- 2015-12-10 JP JP2015240775A patent/JP2016094442A/ja active Pending
-
2016
- 2016-03-09 PH PH12016500461A patent/PH12016500461A1/en unknown
- 2016-03-17 IL IL244648A patent/IL244648A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505637A5 (enExample) | ||
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP2017503835A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| CA2896976C (en) | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | |
| JP2016531126A5 (enExample) | ||
| JP2017504642A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| JP2017526677A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2015025011A5 (enExample) | ||
| JP2013523846A5 (enExample) | ||
| JP2016504400A5 (enExample) | ||
| JP2017522300A5 (enExample) | ||
| JP2014506582A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2018514590A5 (enExample) | ||
| JP2015521195A5 (enExample) | ||
| RU2016104844A (ru) | Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора |